Acelyrin (SLRN) News Today → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free SLRN Stock Alerts $4.68 -0.20 (-4.10%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAcelyrin Founder Steps Down as CEOmarketwatch.com - May 9 at 10:47 PMAcelyrin names Mina Kim as new Chief Executive Officermsn.com - May 9 at 10:47 PMAcelyrin (NASDAQ:SLRN) Price Target Cut to $18.00marketbeat.com - May 9 at 5:39 PMACELYRIN, INC. Announces Leadership Transitionfinance.yahoo.com - May 9 at 8:21 AMACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestonesglobenewswire.com - May 9 at 8:01 AMAcelyrin, Inc. (NASDAQ:SLRN) Given Average Rating of "Moderate Buy" by Brokeragesamericanbankingnews.com - May 9 at 3:28 AMAcelyrin (SLRN) to Release Earnings on Mondaymarketbeat.com - May 6 at 9:27 AMAcelyrin (SLRN) & The Competition Financial Analysisamericanbankingnews.com - May 1 at 5:38 AMACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024globenewswire.com - April 29 at 4:05 PMVontobel Holding Ltd. Purchases Shares of 325,549 Acelyrin, Inc. (NASDAQ:SLRN)marketbeat.com - April 19 at 5:37 AMAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.10marketbeat.com - April 17 at 10:51 AMAcelyrin (NASDAQ:SLRN) Shares Down 5.1% marketbeat.com - April 16 at 3:23 PMAcelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 14 at 4:07 AMAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.61marketbeat.com - April 10 at 10:44 AMAcelyrin, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.82) Per Share (NASDAQ:SLRN)marketbeat.com - April 3 at 6:00 AMResearch Analysts Issue Forecasts for Acelyrin, Inc.'s Q1 2024 Earnings (NASDAQ:SLRN)marketbeat.com - April 2 at 6:22 AMStocks Pressured as Bond Yields Jump on Strength in US Manufacturingmsn.com - April 1 at 12:50 PMACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy Ratingmarkets.businessinsider.com - April 1 at 12:50 PMAcelyrin's (SLRN) Buy Rating Reaffirmed at HC Wainwrightmarketbeat.com - April 1 at 8:23 AMSLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023investorplace.com - March 28 at 11:31 PMACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlightsfinance.yahoo.com - March 28 at 4:17 PMACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlightsglobenewswire.com - March 28 at 4:05 PMAcelyrin (NASDAQ:SLRN) Shares Down 6.3% marketbeat.com - March 21 at 4:24 PMWells Fargo & Company Raises Acelyrin (NASDAQ:SLRN) Price Target to $13.00marketbeat.com - March 21 at 8:36 AMBuy Rating on ACELYRIN, INC.: Promising Clinical Prospects for Novel TED Therapy Lonigutamabmarkets.businessinsider.com - March 20 at 6:47 PMAcelyrin Announces Positive Phase 1/2 Data For Lonigutamab In Thyroid Eye Disease; Stock Upmarkets.businessinsider.com - March 20 at 6:47 PMInvestors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patientsmsn.com - March 20 at 6:47 PMACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Diseasefinance.yahoo.com - March 20 at 6:47 PMAcelyrin, Inc. (NASDAQ:SLRN) Given Average Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - March 20 at 1:29 PMHC Wainwright Reaffirms Buy Rating for Acelyrin (NASDAQ:SLRN)marketbeat.com - March 20 at 12:32 PMAcelyrin (NASDAQ:SLRN) Shares Gap Down to $7.84marketbeat.com - March 18 at 11:24 AMSLRN Apr 2024 2.500 putfinance.yahoo.com - March 18 at 2:42 AMWalleye Capital LLC Acquires New Stake in Acelyrin, Inc. (NASDAQ:SLRN)marketbeat.com - March 15 at 5:21 AMAcelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritisseekingalpha.com - March 12 at 8:53 PMHold Rating Affirmed for ACELYRIN, INC. as Izokibep Faces Competitive Hurdles and Safety Concernsmarkets.businessinsider.com - March 12 at 12:34 PMAdage Capital Partners GP L.L.C. Sells 270,000 Shares of Acelyrin, Inc. (NASDAQ:SLRN)marketbeat.com - March 12 at 5:54 AMAcelyrin Stock Climbs 10% on Positive Results for Arthritis Treatmentmarketwatch.com - March 11 at 3:15 PMAcelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Studymsn.com - March 11 at 3:15 PMAcelyrin's Phase2b/3 Trial Of Izokibep In Psoriatic Arthritis Meets Primary Endpointmarkets.businessinsider.com - March 11 at 10:14 AMACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritisglobenewswire.com - March 11 at 8:02 AMACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patientsglobenewswire.com - March 11 at 8:00 AMSchonfeld Strategic Advisors LLC Acquires 147,454 Shares of Acelyrin, Inc. (NASDAQ:SLRN)marketbeat.com - March 8 at 6:26 AMAcelyrin (NASDAQ:SLRN) Trading Down 6.9%marketbeat.com - March 5 at 3:18 PMFred Alger Management LLC Sells 956,843 Shares of Acelyrin, Inc. (NASDAQ:SLRN)marketbeat.com - March 3 at 7:59 AMAcelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Fmr LLCmarketbeat.com - February 28 at 5:28 AMAcelyrin (NASDAQ:SLRN) Trading Up 11.3%marketbeat.com - February 26 at 11:55 AMEagle Asset Management Inc. Sells 161,687 Shares of Acelyrin, Inc. (NASDAQ:SLRN)marketbeat.com - February 26 at 7:58 AMRafferty Asset Management LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN)marketbeat.com - February 23 at 5:47 AMBarclays PLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN)marketbeat.com - February 20 at 4:23 AMAcelyrin (NASDAQ:SLRN) Trading Up 9%marketbeat.com - February 16 at 2:56 PM Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… SLRN Media Mentions By Week SLRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRN News Sentiment▼0.190.46▲Average Medical News Sentiment SLRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRN Articles This Week▼103▲SLRN Articles Average Week Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANNX News BMEA News MRSN News LXRX News CRBP News RVNC News ADCT News ESPR News MREO News ANRO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRN) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
